- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06355375
Exercise in Pregnancy and Risk of Postpartum Depression
April 4, 2024 updated by: Gabriele Saccone, Federico II University
The prevalence of postpartum depression (PPD) varies between 11.9% and 19.2% during the perinatal period.
PPD refers to minor and major depression incidents that occur during pregnancy or shortly after (up until 12 months after birth).
The symptoms of PPD embrace feeling sad or having a depressed mood, being uninterested in the new-born, unreasonable crying and fear of injuring or harming the baby.
Consequently, PPD can negatively impact the mother's well-being and the baby's development.
The impact on a child can be short for cognitive and motor development .
Although medication is a feasible alternative, many women have constraints due to continuing breastfeeding.
Therefore, exercise can be an alternative that could help to deal with PPD.
Exercise can be used as a preventive or treatment of mild depression at an early stage and as an addition to a treatment plan for major depressive disorder.
Exercising during pregnancy and postpartum improves psychological health and also benefits physical fitness, weight gain control and the prevention or reduction of musculoskeletal discomfort and pain.
Therefore, the American College of Obstetrics and Gynaecologists has recommended that women during pregnancy and postpartum engage in moderate-intensity physical activity almost every day for 30 min a day
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The prevalence of postpartum depression (PPD) varies between 11.9% and 19.2% during the perinatal period.
PPD refers to minor and major depression incidents that occur during pregnancy or shortly after (up until 12 months after birth).
The symptoms of PPD embrace feeling sad or having a depressed mood, being uninterested in the new-born, unreasonable crying and fear of injuring or harming the baby.
Consequently, PPD can negatively impact the mother's well-being and the baby's development.
The impact on a child can be short for cognitive and motor development .
Although medication is a feasible alternative, many women have constraints due to continuing breastfeeding.
Therefore, exercise can be an alternative that could help to deal with PPD.
Exercise can be used as a preventive or treatment of mild depression at an early stage and as an addition to a treatment plan for major depressive disorder.
Exercising during pregnancy and postpartum improves psychological health and also benefits physical fitness, weight gain control and the prevention or reduction of musculoskeletal discomfort and pain.
Therefore, the American College of Obstetrics and Gynaecologists has recommended that women during pregnancy and postpartum engage in moderate-intensity physical activity almost every day for 30 min a day
Study Type
Interventional
Enrollment (Estimated)
398
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gabriele Saccone, MD
- Phone Number: 3394685179
- Email: gabriele.saccone.1990@gmail.com
Study Locations
-
-
-
Naples, Italy, 80100
- Recruiting
- Gabriele Saccone
-
Contact:
- Gabriele Saccone
- Phone Number: 0817461111
- Email: gabriele.saccone.1990@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- singleton gestation
- low risk pregnancy
- age between 20 and 40
Exclusion Criteria:
- high risk pregnancy
- multiple gestation
- prior post partum depression
- any psychiatric disase
- controindication for exercise
- lung or heart disease
- prior preterm birth
- IVF pregnancy
- women who already perform agonistic sport activity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: exercise
aerobic exercise during pregnancy
|
aerobic exercise
|
|
No Intervention: no exercise
no recommendation regarding exercise
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
edinburgh depression scale
Time Frame: 3 months after delivery
|
Edinburgh Postnatal Depression Scale (EDPS)
|
3 months after delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postpartum depression
Time Frame: 3 months after delivery
|
DSM-5 (SCID-5)
|
3 months after delivery
|
|
preterm birth
Time Frame: 37 weeks of gestation
|
defined as delivery before 37 weeks of gestation
|
37 weeks of gestation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2024
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
March 22, 2024
First Submitted That Met QC Criteria
April 4, 2024
First Posted (Actual)
April 9, 2024
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 4, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02.24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.